Latest News

Opsona Therapeutics Ltd. to present preliminary results at the 58th Annual Meeting of the American Society of Hematology (ASH)

November 22 2016, Dublin, Ireland – Seroba's investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it will present preliminary results from its ongoing prospective, open label Phase I/II study being conducted...


Veryan Medical announces the completion of enrolment into the MIMICS-2 clinical study of its BioMimics 3D® Stent System

24 October 2016 - The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration (FDA) Investigational Device Exemption (IDE), with Japanese Pharmaceuticals and Medical...


Opsona Therapeutics Ltd. receives orphan designation for myelodysplastic syndrome (MDS) with OPN-305, a first-in-class monoclonal antibody that blocks Toll-Like Receptor 2

October 25th, 2016, Dublin, Ireland – Seroba's investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States Food and Drug Administration for...


< back to home page